Most pharmacogentic strategies to date have focused on the role of single genes in the regulation of drug activity and have made important steps towards the goal of optimizing therapy for individual patients. However, there is clear evidence that medications, like most common disease, are under the control of a network of genes each contributing to the patient's phenotype. The CREATE Pharmacogenetic Research Network (Comprehensive Research on Expressed Alleles in Therapeutic Evaluation will bring together infrastructure for the evaluation of pathways regulating drug activity This will be achieved through the coordinated efforts of investigators from Washington University and University of Southern California with expertise in the fields of genomics, Pharmacogenetics, Clinical Pharmacology, Bioinformatics/Computational Biology, Molecular Genetics, Statistical Genetics, Population Genetics, Clinical Trials, and Translational Research. Together they will evaluate the following general aims to develop validation strategies for applied pharmacokinetics. General aims: 1. Identify polymorphisms in genes that are components of pathways regulating drug activity 2. Determine the genotype-expression relationship in therapeutically relevant tissue 3. Establish the population characteristics of polymorphisms in Caucasian, Hispanic, Asian, and African American subjects 4. Provide clinical validation of polymorphisms in pathways regulating drug activity These aims will be achieved using human gastrointestinal cancer as a model system, as it is a common cause of death, has no clear prognostic tools to guide therapy, has ethnic differences in incidence and outcome, has readily accessible tissues available in the Tissue Procurement Core facilities, and is treatment with a small number of medications (three drugs). Defined gene pathways are clear for these agents and the Network will identify and evaluate a comprehensive approach to pharmacogenetics.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project--Cooperative Agreements (U01)
Project #
1U01GM063340-01
Application #
6340478
Study Section
Special Emphasis Panel (ZRG1-PHRA (01))
Program Officer
Long, Rochelle M
Project Start
2001-08-01
Project End
2005-07-31
Budget Start
2001-08-01
Budget End
2002-07-31
Support Year
1
Fiscal Year
2001
Total Cost
$2,095,429
Indirect Cost
Name
Washington University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
062761671
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Marsh, Sharon; King, Cristi R; Van Booven, Derek J et al. (2015) Pharmacogenomic assessment of Mexican and Peruvian populations. Pharmacogenomics 16:441-8
Patel, Jai N; Jiang, Chen; Hertz, Daniel L et al. (2015) Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance). Cancer 121:1025-31
Hariani, Gunjan D; Lam, Ernest T; Lam, Ernest J et al. (2014) Application of next generation sequencing to CEPH cell lines to discover variants associated with FDA approved chemotherapeutics. BMC Res Notes 7:360
McWhinney-Glass, Sarah; Winham, Stacey J; Hertz, Daniel L et al. (2013) Cumulative genetic risk predicts platinum/taxane-induced neurotoxicity. Clin Cancer Res 19:5769-76
Trammel, Morgan; Roederer, Mary; Patel, Jai et al. (2013) Does pharmacogenomics account for variability in control of acute chemotherapy-induced nausea and vomiting with 5-hydroxytryptamine type 3 receptor antagonists? Curr Oncol Rep 15:276-85
Motsinger-Reif, Alison A; Jorgenson, Eric; Relling, Mary V et al. (2013) Genome-wide association studies in pharmacogenomics: successes and lessons. Pharmacogenet Genomics 23:383-94
Crowley, James J; Kim, Yunjung; Szatkiewicz, Jin Peng et al. (2012) Genome-wide association mapping of loci for antipsychotic-induced extrapyramidal symptoms in mice. Mamm Genome 23:322-35
He, Y J; McLeod, H L (2012) Ready when you are: easing into preemptive pharmacogenetics. Clin Pharmacol Ther 92:412-4
Hoskins, Janelle M; Ong, Pei-Shi; Keku, Temitope O et al. (2012) Association of eleven common, low-penetrance colorectal cancer susceptibility genetic variants at six risk loci with clinical outcome. PLoS One 7:e41954
Crowley, J J; Adkins, D E; Pratt, A L et al. (2012) Antipsychotic-induced vacuous chewing movements and extrapyramidal side effects are highly heritable in mice. Pharmacogenomics J 12:147-55

Showing the most recent 10 out of 181 publications